Very late acute myeloid leukemia relapse: clinical features, treatment and outcome.

P9 showed a different molecular profile, I FLT3-TKD+/NPM1 i + at diagnosis and I FLT3/TKD i and I NPM1 i wild type at relapse; however, at relapse the patient presented as myeloid sarcoma of the skin. At diagnosis, this patient received intensive chemotherapy followed by PBSCT; at relapse, he was treated with high dose cytarabine plus intrathecal therapy followed by an allogeneic transplant. The occurrence of an acute myeloid leukemia (AML) relapse is generally observed within 2-3 years after complete remission (CR) and affects the overall survival rate of these patients [[1]]. Aim of our study was to evaluate, in a large series of AML patients diagnosed at our Center, the incidence of very late AML relapses, in addition, the therapeutic strategies and the outcome of these patients. [Extracted from the article]